SMEI(SZ:300456) 智通财经网·2025-09-22 11:58Group 1 - The National Integrated Circuit Industry Investment Fund reduced its stake in Saiwei Electronics by 634.81 million shares, representing 0.87% of the total share capital, decreasing its holding from 7.82% to 6.95% [1] - As of the end of Q2, the fund held 8.75% of Saiwei Electronics, making it the second-largest shareholder [1] Group 2 - Changchuan Technology expects a net profit of 827 million to 877 million yuan for the first three quarters of 2025, reflecting a year-on-year growth of 131% to 145% [2] - The growth is attributed to strong market demand in the semiconductor industry and a significant increase in sales revenue [2] Group 3 - Zhixiang Jintai signed exclusive commercialization agreements with Kangzhe Pharmaceutical for two monoclonal antibody injection products, securing upfront and milestone payments totaling approximately 510 million yuan [3] Group 4 - Oriental Pearl plans to invest 244 million yuan in the Advanced Computing Phase II Fund, which will acquire equity in Super Fusion Digital Technology Co., Ltd [4] - The total fundraising size of the fund is 714 million yuan, with the company's investment amounting to 499 million yuan in total [4] Group 5 - Guangli Micro announced an inquiry transfer price of 65 yuan per share, which is a 28% discount compared to the closing price of 90.46 yuan per share [5] - The inquiry transfer was fully subscribed by 24 institutional investors, with a total of 612.73 million shares to be transferred [5] Group 6 - Fourhui Fushi's controlling shareholder reduced its stake by 38.52 million shares between September 12 and September 19, 2025, resulting in a decrease in their holding from 64.96% to 63.82% [6] Group 7 - Tian Shili's subsidiary received approval for a new indication for its drug, making it the only approved recombinant human urokinase product in China for treating acute ischemic stroke [7] - This approval expands the company's product line in the neurology/psychiatry field [7] Group 8 - Yabao Pharmaceutical decided to terminate the clinical trial for SY-009 and will recognize an asset impairment provision of 55.7933 million yuan, which will reduce the company's total profit for 2025 by the same amount [8] - The decision was made due to the uncertainty and significant investment required for further development of the drug [8]